DOCSLIB.ORG

FTSE Global All Cap Ex Canada China a Inclusion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FTSE Global All Cap Ex Canada China a Inclusion FTSE PUBLICATIONS FTSE Global All Cap ex Canada 20 May 2017 China A Inclusion Indicative Index Weight Data as at Closing on 31 March 2017 Index Index Index Constituent Country Constituent Country Constituent Country weight (%) weight (%) weight (%) 13 Holdings <0.005 HONG KONG Acerinox <0.005 SPAIN Aeon Fantasy <0.005 JAPAN 1st Source <0.005 USA Aces Electronic Co. Ltd. <0.005 TAIWAN AEON Financial Service <0.005 JAPAN 2U <0.005 USA Achilles <0.005 JAPAN Aeon Mall <0.005 JAPAN 361 Degrees International (P Chip) <0.005 CHINA Achillion Pharmaceuticals <0.005 USA AerCap Holdings N.V. 0.02 USA 3-D Systems <0.005 USA ACI Worldwide 0.01 USA Aeroflot <0.005 RUSSIA 3i Group 0.02 UNITED Ackermans & Van Haaren 0.01 BELGIUM Aerojet Rocketdyne Holdings <0.005 USA KINGDOM Acom <0.005 JAPAN Aeroports de Paris 0.01 FRANCE 3M Company 0.26 USA Aconex <0.005 AUSTRALIA Aerospace Communications Holdings (A) <0.005 CHINA 3S Korea <0.005 KOREA Acorda Therapeutics <0.005 USA Aerospace Hi-Tech (A) <0.005 CHINA 3SBio (P Chip) <0.005 CHINA Acron JSC <0.005 RUSSIA Aerosun (A) <0.005 CHINA 77 Bank <0.005 JAPAN ACS Actividades Cons y Serv 0.01 SPAIN AeroVironment <0.005 USA 888 Holdings <0.005 UNITED Actelion Hldg N 0.06 SWITZERLAND AES Corp. 0.02 USA KINGDOM Activision Blizzard 0.08 USA AES Gener S.A. <0.005 CHILE 8x8 <0.005 USA Actuant Corp <0.005 USA AES Tiete Energia SA UNIT <0.005 BRAZIL A P Moller - Maersk A 0.02 DENMARK Acuity Brands Inc 0.02 USA Aetna 0.1 USA A P Moller - Maersk B 0.02 DENMARK Acxiom Corp <0.005 USA AF AB <0.005 SWEDEN A.G.V. Products <0.005 TAIWAN Adana Cimento(A) <0.005 TURKEY Affiliated Managers Group 0.02 USA a2 Milk <0.005 NEW ZEALAND Adani Enterprises <0.005 INDIA Aflac 0.06 USA A2A 0.01 ITALY Adani Ports and Special Economic Zone 0.01 INDIA Africa Israel Properties <0.005 ISRAEL AA <0.005 UNITED Adani Power <0.005 INDIA African Rainbow Minerals Ltd <0.005 SOUTH AFRICA KINGDOM Adaro Energy PT <0.005 INDONESIA Afyon Cimento <0.005 TURKEY AAC Technologies Holdings 0.02 HONG KONG Adastria Holdings <0.005 JAPAN Agabang&Company <0.005 KOREA AAK <0.005 SWEDEN A-Data Technology <0.005 TAIWAN AGCO Corp 0.01 USA Aalberts Industries 0.01 NETHERLANDS Adcock Ingram Holdings <0.005 SOUTH AFRICA Ageas 0.02 BELGIUM Aamal Co. Q.S.C. <0.005 QATAR Adcorp Holdings <0.005 SOUTH AFRICA AGFA-Gevaert <0.005 BELGIUM Aaon Inc <0.005 USA Adecco Group AG 0.03 SWITZERLAND Aggreko 0.01 UNITED AAR Corp <0.005 USA Adecoagro SA <0.005 USA KINGDOM Aareal Bank AG 0.01 GERMANY Adeka <0.005 JAPAN Agile Group Holdings (P Chip) <0.005 CHINA Aarons Inc. <0.005 USA Adelaide Brighton <0.005 AUSTRALIA Agilent Technologies 0.04 USA Abacus Property Group <0.005 AUSTRALIA Adhi Karya Persero <0.005 INDONESIA Agios Pharmaceuticals <0.005 USA Abaxis Inc <0.005 USA Adidas 0.09 GERMANY AGL Energy 0.03 AUSTRALIA ABB 0.1 SWITZERLAND Adient plc 0.02 USA AGNC Investment 0.01 USA ABB India <0.005 INDIA Aditya Birla Fashion and Retail <0.005 INDIA Agricultural Bank of China (A) 0.01 CHINA Abbott Laboratories 0.17 USA Aditya Birla Nuvo <0.005 INDIA Agricultural Bank of China (H) 0.03 CHINA AbbVie Inc 0.24 USA Adlink Technology <0.005 TAIWAN Aguas Andinas S.A. A <0.005 CHILE ABC-Mart <0.005 JAPAN Administradora Fibra Danhos S.A. de C.V. <0.005 MEXICO Agung Podomoro Land Tbk PT <0.005 INDONESIA Abercrombie & Fitch A <0.005 USA Admiral Group 0.01 UNITED Ahnlab <0.005 KOREA Aberdeen Asset Management 0.01 UNITED KINGDOM Ahold Delhaize 0.06 NETHERLANDS KINGDOM ADO Properties SA <0.005 GERMANY Ai Holdings <0.005 JAPAN Abertis Infraestructuras 0.02 SPAIN Adobe Systems Inc 0.15 USA AIA Engineering <0.005 INDIA Ability Enterprise <0.005 TAIWAN Adtran Inc <0.005 USA AIA Group Ltd. 0.17 HONG KONG Abiomed Inc 0.01 USA Aduro Biotech <0.005 USA Aica Kogyo <0.005 JAPAN Able C&C <0.005 KOREA Advan <0.005 JAPAN Aichi Bank Ltd <0.005 JAPAN ABM Industries Inc 0.01 USA Advance Auto Parts 0.02 USA Aichi Corp <0.005 JAPAN ABN AMRO Group NV 0.02 NETHERLANDS Advanced Ceramic X <0.005 TAIWAN Aichi Steel <0.005 JAPAN Aboitiz Equity Ventures 0.01 PHILIPPINES Advanced Drainage Systems <0.005 USA Aida Engineering <0.005 JAPAN Aboitiz Power <0.005 PHILIPPINES Advanced Energy Industries 0.01 USA Aier Eye Hospital Group (A) <0.005 CHINA Abu Dhabi Commercial Bank 0.01 UAE Advanced Info Serv 0.01 THAILAND Aiful <0.005 JAPAN Acacia Communications <0.005 USA Advanced International Multitech <0.005 TAIWAN Ain Pharmaciez <0.005 JAPAN Acacia Mining <0.005 UNITED Advanced Micro Dev 0.03 USA Ainsworth Game Technology Ltd <0.005 AUSTRALIA KINGDOM Advanced Process Systems <0.005 KOREA Aiphone <0.005 JAPAN Acadia Healthcare 0.01 USA Advanced Semiconductor Engineering 0.02 TAIWAN Air Arabia <0.005 UAE Acadia Pharmaceuticals 0.01 USA Advanced Technology & Materials (A) <0.005 CHINA Air China (A) <0.005 CHINA Acadia Realty 0.01 USA Advanced Wireless Semiconductor <0.005 TAIWAN Air China (H) <0.005 CHINA AcBel Polytech <0.005 TAIWAN AdvanSix <0.005 USA Air France-KLM <0.005 FRANCE ACC <0.005 INDIA Advantech 0.01 TAIWAN Air Lease 0.01 USA Acceleron Pharma Inc <0.005 USA Advantest Corp 0.01 JAPAN Air Liquide 0.1 FRANCE Accelink Technologies (A) <0.005 CHINA Advisory Board Co <0.005 USA Air Methods <0.005 USA Accell Group <0.005 NETHERLANDS Advtech <0.005 SOUTH AFRICA Air New Zealand <0.005 NEW ZEALAND Accenture Cl A 0.18 USA AECI <0.005 SOUTH AFRICA Air Products And Chemcom 0.07 USA Acciona S.A. <0.005 SPAIN AECOM 0.01 USA Air Water 0.01 JAPAN ACCO Brands <0.005 USA Aedifica <0.005 BELGIUM AirAsia <0.005 MALAYSIA Accor 0.02 FRANCE Aegean Airlines SA <0.005 GREECE AirAsia X <0.005 MALAYSIA Accordia Golf Trust <0.005 SINGAPORE Aegion Corp. <0.005 USA Airbus 0.09 FRANCE Accton Technology <0.005 TAIWAN Aegon NV 0.02 NETHERLANDS Aircastle <0.005 USA Ace Hardware Indonesia <0.005 INDONESIA Aena S.A. 0.02 SPAIN Airport City Ltd <0.005 ISRAEL Acea <0.005 ITALY Aeon 0.02 JAPAN Airport Facilities <0.005 JAPAN Acer <0.005 TAIWAN AEON DELIGHT <0.005 JAPAN Airports of Thailand 0.01 THAILAND Source: FTSE Group 1 of 36 20 May 2017 Index Index Index Constituent Country Constituent Country Constituent Country weight (%) weight (%) weight (%) Airtac International Group <0.005 TAIWAN ALS 0.01 AUSTRALIA Angel Yeast (A) <0.005 CHINA Aisan Industry <0.005 JAPAN Alsea S.A.B. de C.V. <0.005 MEXICO Anglo American 0.04 UNITED Aisin Seiki Co 0.02 JAPAN ALSO Holding AG <0.005 SWITZERLAND KINGDOM Aisino Corporation (A) <0.005 CHINA Alstom 0.01 FRANCE Anglo American Platinum <0.005 SOUTH AFRICA Aixtron <0.005 GERMANY Alstria Office <0.005 GERMANY Anglogold Ashanti 0.01 SOUTH AFRICA Ajanta Pharma <0.005 INDIA Altek Corp <0.005 TAIWAN Anheuser-Busch InBev 0.2 BELGIUM Ajinomoto Co 0.02 JAPAN Alten <0.005 FRANCE Anhui Anke Biotechnology (Group) (A) <0.005 CHINA Ajisen China Holdings (P Chip) <0.005 CHINA Altice NV A 0.02 NETHERLANDS Anhui Chaodong Cement (A) <0.005 CHINA AK Holdings <0.005 KOREA Altice NV B 0.01 NETHERLANDS Anhui Conch Cement (A) <0.005 CHINA AK Steel Holding 0.01 USA Altisource Portfolio Solutions S.A. <0.005 USA Anhui Conch Cement (H) 0.01 CHINA Akamai Technologies 0.02 USA Altisource Residential <0.005 USA Anhui Expressway (A) <0.005 CHINA Akastor ASA <0.005 NORWAY Altium <0.005 AUSTRALIA Anhui Expressway (H) <0.005 CHINA Akbank 0.01 TURKEY Altran Techn. <0.005 FRANCE Anhui Fangxing Science&Technology (A) <0.005 CHINA Akcansa Cimento <0.005 TURKEY Altri SGPS <0.005 PORTUGAL Anhui Golden Seed Winery (A) <0.005 CHINA Akebono Brake Industry <0.005 JAPAN Altria Group 0.32 USA Anhui Gujing Distillery (A) <0.005 CHINA Akenerji Elektrik Uretim <0.005 TURKEY Alumina 0.01 AUSTRALIA Anhui Gujing Distillery (B) <0.005 CHINA Aker <0.005 NORWAY Aluminum Corp of China (A) <0.005 CHINA Anhui Guofeng Plastic Industry (A) <0.005 CHINA Aker BP ASA <0.005 NORWAY Aluminum Corp of China (H) <0.005 CHINA Anhui Heli (A) <0.005 CHINA Aker Solutions ASA <0.005 NORWAY Alupar Investimento S.A. <0.005 BRAZIL Anhui Hengyuan Coal Industry & <0.005 CHINA Akita Bank <0.005 JAPAN Alviva Holdings Ltd <0.005 SOUTH AFRICA Electricity Power (A) Akorn 0.01 USA Amada 0.01 JAPAN Anhui Honglu Steel Construction (group) <0.005 CHINA (A) AKR Corporindo Tbk PT <0.005 INDONESIA Amadeus IT Group SA 0.05 SPAIN Anhui Huamao Textile (A) <0.005 CHINA Aksa Akrilik Ve Kimya Sanayii <0.005 TURKEY Amag Pharmaceuticals <0.005 USA Anhui Huilong Agricultural Means of <0.005 CHINA Aksa Enerji Uretim AS <0.005 TURKEY Amanat Holdings PJSC <0.005 UAE Production (A) Aksigorta <0.005 TURKEY Amano Corp <0.005 JAPAN Anhui Jianghuai Automobile Group (A) <0.005 CHINA Akzo Nobel 0.05 NETHERLANDS Amara Raja Batteries <0.005 INDIA Anhui Jiangnan Chemical Industry (A) <0.005 CHINA Al Meera Consumer Goods Co.
Load more

Recommended publications
  • Bay to Bay: China's Greater Bay Area Plan and Its Synergies for US And
    June 2021 Bay to Bay China’s Greater Bay Area Plan and Its Synergies for US and San Francisco Bay Area Business Acknowledgments Contents This report was prepared by the Bay Area Council Economic Institute for the Hong Kong Trade Executive Summary ...................................................1 Development Council (HKTDC). Sean Randolph, Senior Director at the Institute, led the analysis with support from Overview ...................................................................5 Niels Erich, a consultant to the Institute who co-authored Historic Significance ................................................... 6 the paper. The Economic Institute is grateful for the valuable information and insights provided by a number Cooperative Goals ..................................................... 7 of subject matter experts who shared their views: Louis CHAPTER 1 Chan (Assistant Principal Economist, Global Research, China’s Trade Portal and Laboratory for Innovation ...9 Hong Kong Trade Development Council); Gary Reischel GBA Core Cities ....................................................... 10 (Founding Managing Partner, Qiming Venture Partners); Peter Fuhrman (CEO, China First Capital); Robbie Tian GBA Key Node Cities............................................... 12 (Director, International Cooperation Group, Shanghai Regional Development Strategy .............................. 13 Institute of Science and Technology Policy); Peijun Duan (Visiting Scholar, Fairbank Center for Chinese Studies Connecting the Dots ..............................................
    [Show full text]
  • Fiscal Year 2020 CERTIFICATION of REGISTRATION
    5femnzh Fiscal Year 2020 CERTIFICATION OF REGISTRATION This certifies that: GUANGDONG FEI FAN MSTAR TECHNOLOGY LTD A1 workshop, No.10, Dongnan Xincun Avenue,zone 2,caobian No.3 Industrial Zone,Dali Town ,Nanhai District, Foshan, Guangdong, 528200, CHINA has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration, through Shenzhen CTB Testing Technology Co., Ltd. Owner/Operator Number: 10062900 Device Listing#: See annex CTB will confirm that such registration remains effective upon request and presentation of this certificate until the end of the calendar year stated above, unless said registration is terminated after issuance of this certificate. CTB makes no other representations or warranties, nor does this certificate make any representations or warranties to any person or entity other than the named certificate holder, for whose sole benefit it is issued. This certificate does not denote endorsement or approval of the certificate-holder’s device or establishment by the U.S. Food and Drug Administration. CTB assumes no liability to any person or entity in connection with the foregoing. Pursuant to 21 CFR 807.39, “Registration of a device establishment or assignment of a registration number does not in any way denote approval of the establishment or its products. Any representation that creates an impression of official approval because of registration or possession of a registration number is misleading and constitutes misbranding.” The U.S. Food and Drug Administration does not issue a certificate of registration, nor does the U.S. Food and Drug Administration recognize a certificate of registration, CTB is not affiliated with the U.S.
    [Show full text]
  • Pharma China 201706.Indd
    TM C O N T E N T S I s s u e Editorial of the USFDA CDER and ICH 23 ■ Out of the Blue, CFDA Proposes Giant Legal/IPR News Steps Forward to Boost Drug Innovation ■ China, India Named by USTR on Lax IP 23 and IP Protection 2 130 ■ I-MAK Challenges Gilead's Remaining News in Focus June Patents of HCV Drug Sofosbuvir 24 ■ State Council Issues Document on Major API/Bulk Drug News Healthcare Reform Tasks in 2017 6 ■ U.S. FDA Warns Chinese API Producer 24 2017 ■ Financial Overview of Urban and Rural BMI Programs in 2016 7 ■ DSM Sinochem Won Indian Patent Lawsuit 24 ■ CFDA Minister Calls for Improved Drug Product/R&D News In This Issue Innovation Environment 8 ■ Sirnaomics Granted Chinese IND Approval ■ CFDA Solicits Comments on New Policy for siRNA Drug for Hypertrophic Scar 25 on Full Product Life Cycle Management 8 Shanghai Pharma Eyes Takeover ■ IMPACT Therapeutics Received Chinese Bid for Germany's Stada ■ CFDA Solicits Comments on New Policy IND Approval for Novel PARP Inhibitor 25 on Accelerating Evaluation and Approval 9 ■ The firm is eyeing a possible deal for Athenex Announces CFDA IND Approval Stada Arzneimittel AG, though it had ■ CFDA Solicits Comments on New Policy for KX-02 Tablet for Glioblastoma 25 yet to any offi cial off er. P13 on Reforming Clinical Trial Regulation 9 ■ Hengrui's Breast Cancer Candidate ■ CFDA Solicits Comments on New Policy Shows Promise in an Early Trial 25 AZ, PKU's BIBDR to Build Joint on Protecting Innovator Rights 10 ■ TaiGen Announces NDA Submission for Lab for Healthcare Big Data Taigexyn IV Formulation to the CFDA 26 The goal is to provide scientifi c evidence The Market ■ China Creates New Kinase-Based Whole- to patients, doctors and government ■ NH Projects Chinese OTC Drug Market to Cell Screening Library 26 thru medical big data analysis under an Grow 6% CAGR in the Next Five Years 11 innovative collaborative research model.
    [Show full text]
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
    [Show full text]
  • VANGUARD INTERNATIONAL EQUITY INDEX FUNDS Form N-Q
    SECURITIES AND EXCHANGE COMMISSION FORM N-Q Quarterly schedule of portfolio holdings of registered management investment company filed on Form N-Q Filing Date: 2018-09-28 | Period of Report: 2018-07-31 SEC Accession No. 0000932471-18-007167 (HTML Version on secdatabase.com) FILER VANGUARD INTERNATIONAL EQUITY INDEX FUNDS Mailing Address Business Address PO BOX 2600 PO BOX 2600 CIK:857489| IRS No.: 000000000 | State of Incorp.:DE | Fiscal Year End: 1031 V26 V26 Type: N-Q | Act: 40 | File No.: 811-05972 | Film No.: 181093806 VALLEY FORGE PA 19482 VALLEY FORGE PA 19482 6106691000 Copyright © 2018 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY Investment Company Act file number: 811-05972 Name of Registrant: VANGUARD INTERNATIONAL EQUITY FUNDS Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482 Name and address of agent for service: Anne E. Robinson, Esquire P.O. Box 876 Valley Forge, PA 19482 Date of fiscal year end: October 31 Date of reporting period: July 31, 2018 Item 1: Schedule of Investments Vanguard Pacific Stock Index Fund Schedule of Investments (unaudited) As of July 31, 2018 Market Value Shares ($000) Common Stocks (99.6%)1 Australia (16.6%) Commonwealth Bank of Australia 1,856,264 103,370 BHP Billiton Ltd. 3,386,626 88,447 Westpac Banking Corp. 3,610,167 79,036 CSL Ltd. 475,901 69,628 Australia & New Zealand Banking Group Ltd.
    [Show full text]
  • June 2015 Healthcare Sector Bulletin-16
    HEALTHCARE SECTOR BULLETIN QUADRIA CAPITAL June 2015 HEALTHCARE TRENDS & IMPACT STORIES Country: Vietnam Headline: Insurers in tie-up with Malaysian hospitals Summary: Several Vietnamese insurance companies have signed a Memorandum of Understanding (MoU) with Malaysian hospitals, under which Vietnamese policyholders would have medical insurance cover when they seek treatment at the participating hospitals. The signing ceremony, which took place last week, involved top Malaysian private hospitals, such as the National Heart Institute, Ramsay Sime Darby Health Care and Pantai Hospital Kuala Lumpur, and insurance providers including Post and Telecommunication Joint Stock Insurance Corporation (PTI), Vietinbank Insurance Company (VBI) and Petrolimex Insurance Corporation (PJICO), reported the Vietnam News Agency. In a statement, Allianz Life Malaysia said that Medisafe provides protection for customers in the event of hospitalisation. Available in seven plans, it offers different levels of benefits, ranging from reimbursement for pre and post hospitalisation treatments to home nursing care and ambulance fees. Other important benefits include out-patient treatment for dengue and fee reimbursement for alternative treatment post-hospitalisation such as chiropractic, chiropody, homeopathy, osteopathy or acupuncture which are usually not part of a hospitalisation and surgical insurance coverage. Link http://www.asiainsurancereview.com/News/View-NewsLetter-Article?id=32896&Type=eDaily Country: India Headline: Pharma outsourcing leads healthcare BPO market in India Summary: Pharmaceutical outsourcing market (excluding contract manufacturing services) accounts for about 75 per cent (or $2.5-3.1 billion) of the India’s medical process outsourcing (MPO) segment which is currently estimated at $3.3–4.2 bn, according to a new Assocham-EY joint study.
    [Show full text]
  • Etf Harvest Msci China a Index
    HARVEST FUNDS (HONG KONG) ETF (AN UMBRELLA UNIT TRUST ESTABLISHED IN HONG KONG) HARVEST MSCI CHINA A INDEX ETF (A SUB-FUND OF THE HARVEST FUNDS (HONG KONG) ETF) UNAUDITED SEMI-ANNUAL REPORT 30 JUNE 2019 www.harvestglobal.com.hk Harvest Global Investments HARVEST FUNDS (HONG KONG) ETF (AN UMBRELLA UNIT TRUST ESTABLISHED IN HONG KONG) HARVEST MSCI CHINA A INDEX ETF (A SUB-FUND OF THE HARVEST FUNDS (HONG KONG) ETF) SEMI-ANNUAL REPORT 1ST JANUARY 2019 TO 30TH JUNE 2019 RESTRICTED HARVEST MSCI CHINA A INDEX ETF (A SUB-FUND OF THE HARVEST FUNDS (HONG KONG) ETF) CONTENTS PAGE Report of the Manager to the Unitholders 1 - 2 Statement of Financial Position (Unaudited) 3 Statement of Comprehensive Income (Unaudited) 4 Statement of Changes in Net Assets Attributable to Unitholders (Unaudited) 5 Statement of Cash Flows (Unaudited) 6 Investment Portfolio (Unaudited) 7 – 27 Statement of Movements in Investment Portfolio (Unaudited) 28 – 67 Performance Record (Unaudited) 68 Underlying Index Constituent Stocks Disclosure (Unaudited) 69 Report on Investment Overweight (Unaudited) 70 Management and Administration 71 - 73 RESTRICTED HARVEST MSCI CHINA A INDEX ETF (A SUB-FUND OF THE HARVEST FUNDS (HONG KONG) ETF) REPORT OF THE MANAGER TO THE UNITHOLDERS Fund Performance A summary of the performance of the Sub-Fund1 is given below (as at 30 June 2019): Harvest MSCI China A Index ETF 1H-2019 (without dividend reinvested) 2 MSCI China A Index 27.12% 3 Harvest MSCI China A Index ETF NAV-to-NAV (RMB Counter) 27.15% 4 Harvest MSCI China A Index ETF Market-to-Market (RMB Counter) 26.56% 3 Harvest MSCI China A Index ETF NAV-to-NAV (HKD Counter) 26.84% 4 Harvest MSCI China A Index ETF Market-to-Market (HKD Counter) 27.34% Source: Harvest Global Investments Limited, Bloomberg.
    [Show full text]
  • 43Gdy6nm9dgg55.Pdf
    Investment Manager: AMP Capital Investors Limited ABN 59 001 777 591 | AFSL 232497 Issuer and Responsible Entity: BetaShares Capital Ltd ABN 78 139 566 868 | AFSL 341181 28 February 2017 Market Announcements Office ASX Limited AMP CAPITAL DYNAMIC MARKETS FUND (HEDGE FUND) (ASX CODE: DMKT) QUARTERLY PORTFOLIO DISCLOSURE We advise that the Fund’s portfolio as at 30 December 2016 comprised the following holdings: Security Weighting (%) Security Weighting (%) ETFs* SPDR S&P/ASX200 Fund 9.82 Vanguard Value ETF 2.09 Vanguard FTSE Emgerging Markets ETF 8.75 Vanguard Materials ETF 1.95 BetaShares FTSE RAFI AU 200 5.18 iShares Global Materials ETF 1.93 iShares Global Financials ETF 3.21 Topix-17 Banks ETF 1.70 Vaneck Vectors Russia ETF 2.74 Lyxor ETF STOXX Europe 600 Banks 1.61 SPDR Bank ETF 2.67 Vanguard Energy ETF 1.61 *Please note underlying ETF exposures are provided below on a weighted consolidated look through basis. AMP Capital Investors Limited 50 Bridge Street Sydney NSW 2000 Australia Client Services 1800 658 404 8.30am-5.30pm | [email protected] ampcapital.com.au For personal use only Important information: This information has been prepared by BetaShares Capital Ltd (ACN 139 566 868 AFS Licence 341181) ("BetaShares") the Responsible Entity and Issuer of the Fund. AMP Capital Investors Limited (“AMP Capital”) (ABN 59 001 777 591, and AFSL 232497) is the investment manager of the Fund and has been appointed by the Responsible Entity to provide investment management and associated services in respect of the Fund. It is general information only and does not take into account any person’s objectives, financial situation or needs.
    [Show full text]
  • Annual Report DBX ETF Trust
    May 31, 2021 Annual Report DBX ETF Trust Xtrackers Harvest CSI 300 China A-Shares ETF (ASHR) Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF (ASHS) Xtrackers MSCI All China Equity ETF (CN) Xtrackers MSCI China A Inclusion Equity ETF (ASHX) DBX ETF Trust Table of Contents Page Shareholder Letter ....................................................................... 1 Management’s Discussion of Fund Performance ............................................. 3 Performance Summary Xtrackers Harvest CSI 300 China A-Shares ETF ........................................... 6 Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF .................................. 8 Xtrackers MSCI All China Equity ETF .................................................... 10 Xtrackers MSCI China A Inclusion Equity ETF ............................................ 12 Fees and Expenses ....................................................................... 14 Schedule of Investments Xtrackers Harvest CSI 300 China A-Shares ETF ........................................... 15 Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF .................................. 20 Xtrackers MSCI All China Equity ETF .................................................... 28 Xtrackers MSCI China A Inclusion Equity ETF ............................................ 33 Statements of Assets and Liabilities ........................................................ 42 Statements of Operations ................................................................. 43 Statements of Changes in Net
    [Show full text]
  • China Chemical Drug Sector Research Analysts INITIATION
    19 January 2015 Asia Pacific/China Equity Research Major Pharmaceuticals (Healthcare CN (Asia)) China Chemical Drug Sector Research Analysts INITIATION Zen Zhou 852 2101 7640 [email protected] Big sheep run faster Iris Wang 852 2101 7646 Figure 1: Using three criteria to screen chemical drug companies [email protected] Strong Attractive Capable R&D commercialization Overall ranking valuation capability Hengrui Sihuan CSPC Huahai Salubris Dawnrays x Sino Biopharm Luye Humanwell CMS Fosun Pharma - Highest, - Lowest. Overall ranking is valued by weighted average of three criteria (Capable R&D:35%, Strong commercialization capability: 35%, Attractive valuation: 30%) Note: The four companies labelled with blue colour are initiated by us this time. Source: Credit Suisse ■ Stay on the sweet spot (Oncology and CNS). We forecast China’s chemical drug sector to deliver 15% CAGR in 2014–16, reaching about Rmb900 bn market size; however, the growth rate will vary among different therapeutic areas due to the higher morbidity rate for chronic diseases related to ageing population, urbanisation and lifestyle changes. We expect oncology drugs (17.5% CAGR in 2014–16) and CNS drugs (18.1% CAGR in 2014–16) to gain market share, while anti-infective drugs (9.5% CAGR in 2014–16) to lose market share. ■ Only the leader will win. China’s chemical drug market is fragmented compared to the global level (CR10: 15% vs 42%), but we see the domestic leading companies are gaining market share. We believe the trend of consolidation will stay stable, driven by: (1) higher barrier for R&D, (2) higher barrier for manufacturers, (3) favourable tender policy and (4) more M&A.
    [Show full text]
  • Emerging Markets Core Equity Portfolio-Institutional Class As of July 31, 2021 (Updated Monthly) Source: State Street Holdings Are Subject to Change
    Emerging Markets Core Equity Portfolio-Institutional Class As of July 31, 2021 (Updated Monthly) Source: State Street Holdings are subject to change. The information below represents the portfolio's holdings (excluding cash and cash equivalents) as of the date indicated, and may not be representative of the current or future investments of the portfolio. The information below should not be relied upon by the reader as research or investment advice regarding any security. This listing of portfolio holdings is for informational purposes only and should not be deemed a recommendation to buy the securities. The holdings information below does not constitute an offer to sell or a solicitation of an offer to buy any security. The holdings information has not been audited. By viewing this listing of portfolio holdings, you are agreeing to not redistribute the information and to not misuse this information to the detriment of portfolio shareholders. Misuse of this information includes, but is not limited to, (i) purchasing or selling any securities listed in the portfolio holdings solely in reliance upon this information; (ii) trading against any of the portfolios or (iii) knowingly engaging in any trading practices that are damaging to Dimensional or one of the portfolios. Investors should consider the portfolio's investment objectives, risks, and charges and expenses, which are contained in the Prospectus. Investors should read it carefully before investing. Your use of this website signifies that you agree to follow and be bound by the terms
    [Show full text]
  • Sinopharm Group: 2H14 NDR Takeaways: Margin Expansion To
    Sinopharm Group | March 25, 2015 MORGAN STANLEY RESEARCH March 25, 2015 MORGAN STANLEY ASIA LIMITED+ Yolanda Hu Sinopharm Group [email protected] +852 2848-5649 Bin Li 2H14 NDR Takeaways: Margin Expansion [email protected] +852 2239-7596 Isabella Zhao to Continue [email protected] +852 2848-5887 Industry View Stock Rating Price Target Attractive Overweight HK$34.00 Sinopharm Group ( 1099.HK , 1099 HK ) China Healthcare / China Stock Rating Overweight Sinopharm’s solid sales growth and operating leverage are likely to Industry View Attractive continue in 2015, despite the uncertain policy outlook for the Price target HK$34.00 Up/downside to price target (%) 15 Healthcare industry. We find the stock attractive at 18x our revised Shr price, close (Mar 24, 2015) HK$29.50 2015e EPS. Reiterate OW. 52-Week Range HK$34.50-19.72 Sh out, dil, curr (mn) 2,568 Healthy 2015 sales outlook: Given decelerating GDP growth expected in Mkt cap, curr (mn) Rmb60,695 EV, curr (mn) Rmb78,243 2015, mgmt looks for growth of the end-user market to slow to 12%, and for Avg daily trading value (mn) HK$133 the distribution industry to grow 14-15%. Management remains confident about achieving its sales target of 3-5% above the market average. Fiscal Year Ending 12/14 12/15e 12/16e 12/17e ModelWare EPS (Rmb) 1.11 1.32 1.51 1.70 Margin improvement to continue in 2015, ... This is the first quarter that Prior ModelWare EPS 1.10 1.29 1.44 1.58 (Rmb) Sinopharm has recorded faster profit growth than sales growth, mainly due to: Consensus EPS (Rmb)§ 1.10 1.30 1.55 1.50 1) internal integration; 2) economies of scale; 3) optimizing customer mix Revenue, net (Rmb 200,131 235,469 272,701 313,245 (more direct sales to hospitals), and 4) more focus on the quality of growth.
    [Show full text]